Heat-shock protein (HSP)-based immunotherapy is established on its adjuvant effects when applied via an extracellular approach to pulse and activate dendritic cells (DCs). Our previous studies indicate that DCs pulsed with recombinant fusion proteins of antigenic fragment and HSP70-like protein 1 (HSP70L1) are potent in stimulating antigen-specific Th1 responses. We herein evaluated the cytotoxic T cell (CTL) response by an intracellular approach of priming DCs with transfection of recombinant adenovirus-expressing the fusion gene of the 576-699 fragment of carcinoembryonic antigen (CEA) and HSP70L1. As compared with DCs pulsed with extracellular fusion protein, the DCs transfected with recombinant adenovirus expressing the fusion gene displayed equivalent mature phenotypes but less inflammatory appearance. However, the transfected DCs were superior to the pulsed DCs in inducing CEA-specific CTLs. Consistently, immunization of HLA-A2.1/H-2K b transgene mice with the transfected DCs could induce more quantities of HLA-A2.1-restricted CEA-specific CTLs, protecting nude mice more significantly from human CEA-expressing colon tumor challenge when adoptively transferred. Mechanistic investigation indicated that intracellular expression of the fusion protein empowered the transfected DCs by activation of STAT1 possibly via inducing IFN-β and ERK pathways. Therefore, the more potent ability to induce anti-CEA CTL responses enables the DCs, which transfected with recombinant adenovirus expressing the fusion gene of antigenic CEA fragment and Th1 adjuvant, as an alternative promising approach for the immunotherapy of CEA-positive tumors.
INTRODUCTION
Heat-shock proteins (HSPs) are highly conserved throughout the evolution from prokaryotes to eukaryotes, serving as a protective system at the time of environmental or pathologic insults such as hyperthemia, oxidative stress, glucose deprivation, heavy metal and viral intrusion, as well as cancerous transformation. 1,2 In human, HSPs are grouped into five main families, including HSP60, HSP70, HSP90, HSP100 and the small HSPs, according to their approximate molecular weight. Under steady physiological status, HSPs within cells function as 'chaperones' or 'cochaperones' participating in the proper conformation, assembly and transport of nascent peptides and degradation of misfolded proteins. 3, 4 Under stress or pathological conditions, some HSP complexes including their chaperoned peptides are released from cells. Some of them such as glucose-regulated protein 96, HSP90 and HSP70 have been identified to possess the activities of adjuvant when outside cells, being helpful for induction of Th1 and cytotoxic T cell (CTL) responses specific for their chaperoned peptides. [5] [6] [7] What are the mechanisms for the adjuvant activities of extracellular HSPs and how to modify HSPs to take the antigenic information for the activation of specific T-cell response remain to be further understood.
Induction of chaperoned peptide-specific immune responses by these HSP complexes is dependent on the presence of 1 Antigen-presenting cells (APCs), particularly dendritic cells (DCs). 8, 9 Extracellular HSPs induce the secretion of inflammatory cytokines and antigen-presenting functional maturation of APCs via activating the pathways of nuclear factor-κB (NF-κB) and mitogen-activated protein kinases (MAPKs). [10] [11] [12] [13] On the other hand, HSPs promote the uptake and internalization of HSP/chaperoned peptide complexes by APCs via interaction with CD91, lectin-like oxidized low-density lipoprotein receptor-1 or other unknown receptors, [14] [15] [16] [17] and enhance the cross-presentation of chaperoned peptides by APCs, subsequently eliciting a robust antigen (Ag)-specific T-cell response. [18] [19] [20] Therefore, most HSP-based immunotherapeutic strategies are established via an extracellular priming approach. Numerous experimental data and several clinical trials have demonstrated that HSP complexes or fusion proteins containing tumor or viral antigens and tumor cell-derived or tumor-DC fusion cell-derived HSP complexes or HSP-containing exosomes display promising efficacy in immunotherapy of tumors and infectious diseases. [21] [22] [23] [24] [25] [26] [27] However, the adjuvant activities of extracellular HSPs once transfected into APCs such as DCs remain to be discovered.
HSP70-like protein 1 (HSP70L1, also HSPA14) belongs to the HSP70 family, which contains at least 11 members with distinct intracellular locations and functions. HSP70L1 within cells is one component of mammalian ribosome-associated complex (mRAC) binding to the ribosome. 28 Intracellular mRAC functions as a J-domain partner of HSP70 by M-phase phosphoprotein 11 (MPP11), another component of mRAC, to enhance the interaction of HSP70 with nascent peptide chains. 29 The exact role of HSP70L1 within cell remains unclear. In Saccharomyces cerevisiae, RAC consists of Ssz1 (ortholog of HSP70L1), Z-DNA-binding protein 1 (ortholog of MPP11) serving as the J-domain protein and ribosomeassociated Ssb1/2 (ortholog of classic HSP70s). Ssz1 may function as a scaffold in organizing Z-DNA-binding protein 1 and Ssbs into ribosomal protein-folding complexes. 30 Similar to HSP70, extracellular HSP70L1 displays the characteristics of adjuvant by its induction of inflammatory responses and the maturation of DCs. [31] [32] [33] Our previous studies have demonstrated that fusion proteins of the 576-669 fragment of carcinoembryonic antigen (CEA 576-669 ) or the 341-456 fragment of human epidermal growth factor receptor-2 that fused to the N terminus of HSP70L1 efficiently induce CEA-specific or human epidermal growth factor receptor-2-specific CTLs by priming DCs via an extracellular approach. 34, 35 We herein transfected human monocyte-derived DCs (MoDCs) with a recombinant adenovirus (Ad) expressing the fusion gene of CEA 576-669 and HSP70L1 (AdCEA 576-669 HSP70L1-DCs), and interestingly found that priming of DCs via this intracellular approach could more efficiently elicit CTL responses for CEA-positive tumor. Our study outlines a new approach to induce antigen-specific antitumor immune response by more efficiently empowering DC vaccination via HSP70L1-mediated intracellular priming.
MATERIALS AND METHODS
Animals, cell lines and reagents HLA-A2.1/H-2K b transgene mice were obtained from Jax Lab (Bar Harbor, ME, USA), and nude mice (C57BL/6 J background) were from Joint Venture Sipper BK Experimental Animal (Shanghai, China). They were bred and housed in appropriate animal care facilities. All experimental manipulations were conducted in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals, with the approval of the Scientific Investigation Board of Second Military Medical University (Shanghai, China).
HEK293 cells, LS-174T, LoVo, SW480 and SW620 cell lines were obtained from American Type Culture Collection (Manassas, VA, USA) and maintained in RPMI 1640 complete medium supplemented with 10% FCS (both from Gibco, Grand Island, NY, USA).
Fluorescence-conjugated antibodies (Abs) were from BD Bioscience (Mountain View, CA, USA) or Biolegend (San Diego, CA, USA), mouse anti-CEA 576-669 HSP70L1 monoclonal antibody (mAb; clone 4E8) and enzyme-linked immunosorbent assay (ELISA) kit for CEA 576-669 HSP70L1 from AbMax (Beijing, China), and purified Abs for intracellular signal molecules from Abcam (Cambridge, UK). Human or mouse recombinant granulocytemacrophage colony-stimulating factor (GM-CSF), interleukin (IL)-4, IL-2 and IL-7 were from R&D (Minneapolis, MN, USA), immunomagnetic microbeads from Miltenyi Biotec (Bergisch Gladbach, Germany), human IL-6, TNFα and IL-12/IL-23p40 CBA beads and interferon (IFN)-γ ELISPOT kits from BD Bioscience, human IFN-β ELISA kit from CUSABIO (Wuhan, China) and carboxyfluorescein diacetate succinimidyl ester (CFSE) from Molecular Probe (Eugene, OR, USA). Nonapeptides of CEA peptide-1 (CAP1), Her2 435-443 , EBV 416-424 , CEA 636-644 , CEA 652-660 and Her2 263-271 were synthesized and purified by Apeptide (Shanghai, China), and the pentamers of HLA-A2/CAP1 and HLA-A24/CEA 652-660 were synthesized and purified by Proimmune (Oxford, UK) and HLA-A11/CEA 636-644 pentamer by Immundex (Copenhagen, Denmark). CEA 576-669 HSP70L1 fusion protein was prepared as previously described. 35 SiRNAs were synthesized by GenePharma (Shanghai, China) and primers by Sangon (Shanghai, China). Sequences of short interfering RNA (siRNA) and primers are listed in Supplementary Table1. Recombinant replication-defective Ad5 without exogenous inserted gene (AdCtrl) was constructed by Hanbio (Shanghai, China).
Preparation of human and mouse DCs
Human MoDCs from peripheral blood of healthy donors, obtained with informed consent and the approval by our institutional review board, and mouse bone marrow-derived DCs were induced in the presence of GM-CSF (50 ng/ml for human, 10ng/ml for mouse) plus IL-4 (10 ng/ml for human, 1 ng/ml for mouse) for 7 or 9 days. Immature human DCs (on d5) or mouse DCs (on d9) were stimulated with CEA 576-669 HSP70L1 (1 μg/ml) or were transfected with Ad vectors at indicated multiplicity of infection (MOI) after treatment with or without siRNAs at 20 nM or inhibitor of ERK signal pathway (UO126, 10 μM). After another 2 days of culture, DCs were collected for the next studies.
Construction and purification of recombinant Ad vectors
Ad expressing the fusion gene of CEA 576-669 HSP70L1 with or without a sequence of signal peptide from human Chemokine CCL17 (Supplementary Table1) at its 5' end, which amplified from the recombinant pQE30 expression vector, 35 was constructed using the pAdEasy1 System (Strategen, La Jolla, CA, USA), and all Ad vectors were packaged in HEK293 cells and purified using the Adeasy virus purification kits (Agilent Technologies, Santa Clara, CA, USA).
MLR
DCs were incubated with allogeneic CD3 + T cells purified by anti-CD3 microbeads at a ratio of 1:20 for 5 days. The proliferation of CD3 + CD4 + and CD3 + CD8 + T cells by CFSE dilution, the production of IFN-γ and IL-17 from Th cells gated as CD3 + CD4 + cells and of granzyme B and perforin from CTLs gated as CD3 + CD8 + cells were detected using FACS.
CTL generation
Purified autogeneic CD3 + T cells and DCs from healthy HLA-A2 + , HLA-A24 + or HLA-A11 + donors were cocultured at an initial ratio of 20:1, and every other 7 days frozen autologous DCs were revived, and similar initial quantities of DCs were added into the DC/T coculture system. Beginning on day 10, 300 U/ml IL-2 and 30 ng/ml IL-7 were added every 2-3 days. After three cycles of culture, cells were collected for FACS analysis or further isolation of CD8 + T cells in CTL or ELISPOT assays.
CTL assay CFSE-labeled tumor cells were cocultured with CD8 + T cells at a ratio of 1:30 overnight, and then the death of CFSE + cells was evaluated using propidium iodide staining and FACS analysis.
IFN-γ-ELISPOT assay CD8 + T cells (1×10 5 /well) from the autologous DC/T coculture system were seeded onto 96-well polyvinylidene difluoride-backed microplates coated with anti-human IFN-γ mAb in the presence of autogeneic DCs at a ratio of 10:1 and indicated nonapeptide (5 μg/ml) for 24 h, and then cells were removed, and the plates processed following the manufacturer's protocol of the ELISPOT kit. Resulting spots were counted using ImmunoSpot Analyzer (Cellular Technology Ltd., Cleveland, OH, USA). All groups were performed in triplicate.
In vivo assay HLA-A2.1/H-2K b transgene mice (6-8 weeks) were immunized intravenously with 10 6 DCs/mouse (eight mice/group) and boosted every other week for a total of three times. After 7 days of the last immunization, lymphocytes from the spleen and axillary and inguinal lymph nodes were adoptively transferred into SW480 or LS-174 T-loaded nude mice (5 × 10 6 cells/ mouse) or for the HLA-A2.1/CAP1 pentamer analysis. Tumor-loaded models were established by subcutaneous injection of tumor cells (1 × 10 6 /mouse) into the nude mice (6-8 weeks, 6 or 8 mice/group). After 1 week, mice were injected with splenic and lymph node cells from immunized mice for three times at a 1-week interval, and the tumor growth and the survival of tumor-loaded mice were monitored.
Statistical analysis
Statistical analysis was performed using Prism (GraphPad software, La Jolla, CA, USA), and Students' t-test, analysis of variance and log-rank (Mantel-Cox) test and FACS analysis were carried out using software including DIVA, SUITE (BD Bioscience) and FlowJo software (Ashland, OR, USA); significance was established at Po0.05.
RESULTS
The expression and intracellular distribution of CEA 576-669 HSP70L1 fusion protein in AdCEA 576-669 HSP70L1-transfected DCs To detect the effect of intracellular CEA 576-669 HSP70L1 on the maturation and T-cell stimulatory activity of DCs, we transfected human monocyte-derived immature DCs with AdCEA 576-669 HSP70L1 (AdCEA 576-669 HSP70L1-DCs) at indicated MOI for 48 h, and found that AdCEA 576-669 HSP70L1-DCs expressed the highest level of CEA 576-669 HSP70L1 once transfected with the recombinant Ad at a MOI of 100 ( Figure 1a ). Therefore, we selected MOI 100 throughout the subsequent studies. The expression of CEA 576-669 HSP70L1 in AdCEA 576-669 HSP70L1-DCs could be obviously detectable at 6 h, up to peak at 24 h, and significantly downregulated to an undetectable level at 72 h after transfection (Figure 1b) . Therefore, we selected Ad-transfected DCs after 48 h of transfection for the subsequent functional experiments. The amount of CEA 576-669 HSP70L1 in the culture supernatant of AdCEA 576-669 HSP70L1-DCs was undetectable under a steady status, excluding the possibility that the secreted, extracellular CEA 576-669 HSP70L1 could exert the DCs via an autocrine/paracrine way. While under hyperthermia condition CEA 576-669 HSP70L1 could be markedly released from AdCEA 576-669 HSP70L1-DCs into extracellular environments, despite its amount being lower than the level of secreted CEA 576-669 HSP70L1 from DCs transfected with Ad expressing a sequence of signal peptide at the 5' end of the CEA 576-669 HSP70L1 fusion gene (Figure 1c) . Intracellular CEA 576-669 HSP70L1 expressed in the transfected DCs mainly distributed in the cytoplasm but little in the nucleus, and could colocalize with the 60S ribosomal protein L17 (RPL17) subunit of the ribosome (Figure 1d ). Taken together, intracellular CEA 576-669 HSP70L1 by Admediated transfection may exert its function in the cytoplasm of the transfected DCs under steady status.
AdCEA 576-669 HSP70L1-DCs display the characteristics of mature DCs Next, we evaluated the phenotypes and allogeneic T-stimulatory activities of AdCEA 576-669 HSP70L1-DCs. AdCEA 576-669 HSP70L1-DCs expressed higher levels of CD40, CD80, AdCEA 576-669 HSP70L1-DCs induce more potent CEA-specific CD8 + CTL responses As AdCEA 576-669 HSP70L1-DCs display the mature phenotypes of DCs, we evaluated their ability to induce CEA-specific CD8 + CTLs. The CEA 576-669 fragment contains two known major histocompatibility complex (MHC)-I-restricted epitopes, respectively, HLA-A2.1-restricted CAP1 and HLA-A24.2-restricted CEA 652-660 , and one predicted HLA-A11.1-restricted CEA 636-644 using http://www.cbs.dtu.dk/services/NetMHC/. The peptide of CEA 636-644 whether together with or without β2 microglobulin (β2 m) significantly upregulated the expression of HLA-A11 on LoVo cells, a HLA-A11.1 + donor-derived colon tumor cell line but expressing undetectable level of HLA-A11 in the absence of HLA-A11-restricted peptides, and a known HLA-A11.1-restricted EBV 416-424 also upregulated the expression of HLA-I on LoVo cells but at a less extend, whereas peptides of HLA-A2.1-restricted CAP1 and HLA-A24.2-restricted CEA 652-660 had no such effect, indicating that the CEA 636-644 peptide was a potential HLA-A11.1-restricted epitope (Figure 3a) . We stained CD3 + T cells, which had been restimulated by autogeneic DCs with indicated treatments, with pentamers of HLA-A2/CAP1, HLA-A11/ CEA 636-644 or HLA-A24/CEA 652-660 and found that T cell stimulated by autogeneic AdCEA 576-669 HSP70L1-DCs contained more frequencies of the CD8 + T cells, which could bind these pentamers of HLA-A2/CAP1, HLA-A24/CEA 652-660 or HLA-A11/CEA 636-644 than those by DCs, AdCtrl-DCs or CEA 576-669 HSP70L1-DCs ( Figure 3b) . Next, ELISPOT assays demonstrated that autogenous CD8 + T cells stimulated by AdCEA 576-669 HSP70L1-DCs produced more amounts of IFN-γ in response to CAP1, CEA 652-660 or CEA 636-644 peptides as compared with those by DCs, CEA 576-669 HSP70L1-DCs or AdCtrl-DCs (Figure 3c) . (Figure 4a) .
Next, we detected the therapeutic effects of adoptively transferred lymphocytes derived from the immunized mice on the HLA-A2 + CEA + tumor cell-loaded nude mice. We established two CEA-positive tumor models, SW480 or LS-174 T tumor-bearing nude mice, because the two tumor cells in vitro could be killed by CEA-specific CTLs more efficiently than other tumor cells. However, the two tumors have some intrinsic defects, as SW480 cells express HLA-A2 but small amount of CEA, and LS-174 T cells express CEA abundantly but an undetectable level of HLA-A2. We transferred splenic and lymph node cells from the immunized mice into SW480 or LS-174 T-bearing nude mice, and observed that the tumor growth was inhibited (Figures 4b and c) and the survival was improved (Figures 4d and e) , with more pronounced effects in the group of AdCEA 576-669 HSP70L1-DC immunization as compared with that in the group of AdCtrl-DC immunization. Thus, in vivo administration of AdCEA 576-669 HSP70L1-DCs could efficiently induce CEAspecific CTL to kill CEA-positive tumors.
The pathways of STAT1 and ERK are involved in the maturation of AdCEA 576-669 HSP70L1-DCs It has been demonstrated that DCs pulsed by extracellular CEA 576-669 HSP70L1 fusion protein are induced into maturation dependent on the activation of the pathways of MAPKs and NF-κB by TLR4; 32,33 therefore, we investigated which signal pathways were involved in the full maturation of AdCEA 576-669 HSP70L1-DCs. Interestingly, the activation of the STAT1, STAT3 and ERK pathways was significantly enhanced in AdCEA 576-669 HSP70L1-DCs as compared with AdCtrl-DCs, and the activation of the STAT5, STAT6, NF-κB, P38 and JNK pathways was similar in the two DCs (Figure 5a) , suggesting that the pathways in DCs activated by intracellular CEA 576-669 HSP70L1 were different from those by extracellular CEA 576-669 HSP70L1. To investigate the roles of these pathways in the full maturation of AdCEA 576-669 HSP70L1-DCs, we blocked these pathways using siRNA or inhibitors, and found that blockade of the STAT1 or ERK pathway significantly inhibited the maturation of AdCEA 576-669 HSP70L1-DCs; however, blockade of STAT3 and STAT5 had less inhibitory effect (Figure 5b) . Therefore, the intracellular CEA 576-669 HSP70L1 may be responsible for the Ag-presenting functional maturation of DCs via the activation of the STAT1 or ERK pathway. Furthermore, to investigate which mechanisms are involved in the activation of STAT1, we detected the expression of type I IFNs and found that the expression of IFN-α was undetectable in all indicated treated DCs (data not shown), but the secretion of IFN-β was strongly induced in AdCEA 576-669 HSP70L1-DCs (Figure 5c ), suggesting that the activation of STAT1 might be a secondary response to the production of IFN-β.
Intrinsic HSP70L1 is a component of mRAC via interaction with MPP11. We then evaluated whether intracellular CEA 576-669 HSP70L1 could affect the interaction of intrinsic HSP70L1 and MPP11. We found that the expression levels of intrinsic HSP70L1, MPP11 and mRAC-related HSPs such as HSP70 and heat-shock cognate 71-kDa protein (HSC70) were similar in AdCEA 576-669 HSP70L1-DCs and AdCtrl-DCs (Figure 5d) , and the interaction of intrinsic HSP70L1 with MPP11 was also not significantly affected (Figure 5e ). Therefore, intracellular CEA 576-669 HSP70L1 might not be as a potent competitor of intrinsic HSP70L1 to exert significant interference on the roles by intrinsic HSP70L1.
DISCUSSION
Effective induction of tumor-specific CTLs is the crux for tumor immunotherapy. Numerous evidence over the past two decades has indicated that tumor-derived suppressive factors limit the efficacy of several tumor vaccines. HSP-based immunotherapy aims to overcome tumor-derived suppression, which has been confirmed to be excellently effective in a robust body of animal experiments because of its powerful adjuvant effect and Ag cross-presentation function when administered via an extracellular approach. In this study, we show that AdCEA 576-669 HSP70L1-DCs, as an alternative HSP-based vaccine via an intracellular approach, can also efficiently induce CEA-specific CTLs.
AdCEA 576-669 HSP70L1-DCs display the characterisitics of mature DCs dependent on the activation of STAT1 and ERK pathways, among which IFN-β might be responsible for the activation of STAT1, indicating that intracellular CEA 576-669 HSP70L1-triggered signal pathways were distinct from those triggered by extracellular CEA 576-669 HSP70L1, which cannot strongly induced the production of IFN-β but activates NF-κB and MAPKs via TLR4. 32, 33 As the expression of IFN-β can be also induced from control Ad-transfected DCs compared with DCs alone or extracellular CEA 576-669 HSP70L1-pulsed DCs, Figure 5 The pathways of STAT1 and ERK involved in the maturation of AdCEA 576-669 HSP70L1-DCs. (a, d, e) . Immature DCs were transfected with indicated Ad for 24 h, and then the expression or/and phosphorylation of STAT1,3,5,6, ERK, JNK, P38 and P65 (a) and of HSP70L1, MPP11, HSP70, HSC70 and RPL17 (d) was detected using western blot, and the interaction between HSP70L1 and MPP11 was detected using CoIP/western blot (e). (b) Immature DCs were transfected with indicated siRNA (20 nM) or ERK inhibitor (UO126,10μM) 2 h before with indicated Ad for another 48 h, and then the phenotype of DCs was detected using FACS. (c) Immature DCs were pulsed with CEA 576-Ad-mediated infection also contributes to the activation of the STAT1 pathway. Such an effect is consistent with other reports that the replication-defective recombinant Ad deleted in E1-and E3-coding domains activate secondary type I IFNstimulated pathways of STAT1 and STAT2 via Cyclic GMP-AMP synthase/stimulator of IFN genes/TANK-binding kinase 1 DNA-sensing cascade. 36 In addition to IFN-β-induced secondary response, the increased activation of STAT1 in AdCEA 576-669 HSP70L1-DCs might also result from the increase in total STAT1 by intracellular CEA 576-669 HSP70L1. Similar to STAT1, the expression of other STATs including STAT3, STAT5 and STAT6 was also increased in AdCEA 576-669 HSP70L1-DCs. As intracellular CEA 576-669 HSP70L1 mainly localizes in the cytoplasm, indicating it not as a transcription regulator, we therefore speculate that intracellular CEA 576-669 HSP70L1 enhances the expression of STATs via regulating ubiquitin/proteasome-dependent degradation or other mechanisms to be further elucidated. In addition, mechanisms underlying the activation of STAT1 by intracellular CEA 576-669 HSP70L1 beyond the induction of IFN-β and upregulation of the STAT1 expression also remain to be further explored. Interestingly, the inhibition on the STAT5 pathway seems to have no significant affection on the maturation of AdCEA 576-669 HSP70L1-DCs, possibly because of the compensated effects by the activation of the STAT1 and ERK pathways. Although the pathway of STAT5 by GM-CSF is critical for the differentiation of monocytes into DCs, its activation might be redundant for the maturation of MoDCs at the late stage of development because blockade of STAT5 only exerts less inhibitory effect on the expression of co-stimulatory and MHC molecules in AdCtrl-transfected DCs.
Intrinsic HSP70L1 inhibits the activation of the STAT1 pathway as well as the STAT3 pathway, and in fact also inhibits the maturation of DCs, as characterized by the expression of co-stimulatory and MHC molecules on DCs inhibited by overexpression of HSP70L1 but enhanced by blockade of intrinsic HSP70L1 (our unpublished data). The contrast roles in the STAT1 and STAT3 pathways, respectively, by intracellular CEA 576-669 HSP70L1 and intrinsic HSP70L1 imply that the presence of the CEA 576-669 fragment fused to the N terminus of HSP70L1 endowed CEA 576-669 HSP70L1 with novel functions different from intrinsic HSP70L1. We speculated that intracellular CEA 576-669 HSP70L1 might not interact with MPP11 despite its ribosomal colocalization, as the interaction between MPP11 and HSP70L1 was not affected in AdCEA 576-669 HSP70L1-DCs significantly.
Our previous study indicated that DCs pulsed by HSP70L1-based fusion protein were also potent in induction of HLA-A2.1-restricted CTLs. 34, 35 Such ability should be dependent on Ag cross-presentation by HSP70L1, the underlying mechanisms of which remain to be elucidated. In the present study, we showed that CEA 576-669 HSP70L1-pulsed DCs were not as powerful as AdCEA 576-669 HSP70L1-DCs in inducing CTLs. Such difference is possibly because of the reasons that intracellular CEA 576-669 HSP70L1 could follow the classical MHC-I pathway to present antigen, could stimulate the expression of MHC-I more efficiently than extracellular CEA 576-669 HSP70L1 fusion protein via STAT1 and ERK pathways or intracellular CEA 576-669 HSP70L1 might also interact with those yet unknown molecules that mediate Ag cross-presentation by extracellular CEA 576-669 HSP70L1 fusion protein. Another advantage of AdCEA 576-669 HSP70L1-DCs as DC vaccine compared with CEA 576-669 HSP70L1-pulsed DCs is that the amount of inflammatory cytokines including IL-6, TNF-α and IL-12/IL-23p40 produced by AdCEA 576-669 HSP70L1-DCs is less than that by CEA 576-669 HSP70L1-pulsed DCs, which may bring some suppressive effects on antitumor immune responses such as IL-6 or severely inflammatory problems. IL-6 has been identified as a component of the tumor microenvironment that promotes tumor cell growth, invasion, metastasis and drug resistance. 37, 38 In addition, IL-6 as a Th17-type cytokine also promotes the differentiation of Th17, whose frequencies are increased in many human tumors, and derived IL-17 might drive the tumorigenesis, particularly colorectal cancer. 39, 40 As we all know, most colorectal tumors are CEA-producing, therefore, as DC vaccine specific for CEA, CEA 576-669 HSP70L1-pulsed DCs might give rise to some negative effects in vivo via secreting large amounts of IL-6. In addition, excess production of IL-6 together with other inflammatory cytokines may also bring potential cytokine storm when large quantities of CEA 576-669 HSP70L1-pulsed DCs are administered individually. Given that DCs primed by the AdCEA 576-669 HSP70L1-mediated intracellular approach is better in induction of adaptive responses than by the CEA 576-669 HSP70L1-mediated extracellular approach, although the latter is better in eliciting innate responses than the former, HSP70L1-base DC combination vaccines, containing appropriate dosages of AdCEA 576-669 HSP70L1-DCs and CEA 576-669 HSP70L1-DCs, might be more effective than either one individually used.
In summary, we here present an intracellular approach of priming DC for HSP70L1-based tumor immunotherapy. This approach is more outstanding in induction of CEA-specific CTLs but less powerful in stimulating innate responses than the classical extracellular priming approach. Given the pros and cons, combining priming DCs with AdCEA 576-669 HSP70L1 and extracellular CEA 576-669 HSP70L1 is expected to be a promising immunotherapeutic strategy for CEA-positive tumors.
